Novel Advances in Treatments for Childhood Craniopharyngioma
Novel Advances in Treatments for Childhood Craniopharyngioma Webinar
Hosted by The Brain Tumour Charity
Adamantinomatous craniopharyngioma (ACP) is a relatively uncommon, but often neurologically devastating, tumour that imparts substantial social and economic burdens.
Almost universally involving the suprasellar region, ACP’s location and propensity for cyst formation and hypothalamic infiltration confer severe tumour- and therapy-related morbidity, including blindness, hypothalamic obesity, panhypopituitarism, cognitive delays, and decreased life expectancy. For a multitude of reasons, including a limited understanding of the tumour’s biology, no novel therapies for ACP have been established in over 25 years. With support from The Brain Tumour Charity, Professors Hankinson and Martinez-Barbera are collaborating to identify and introduce biologically targeted novel therapies for ACP.
Date: Thursday 28 January 2021
Time: 3:00pm GMT
Duration: 1 hour
Register Today: https://bit.ly/2M8qvF5
Overview of the webinar
- Introduction to the clinical and research background of ACP.
- Discussion of current preclinical research tools and developments.
- Discussion of novel genetically engineered mouse models of ACP.
- Review of current theories regarding the roles of biological processes, such as senescence and inflammation in ACP.
- Update on current clinical trials for children with ACP.
- Q&A
Speakers
- Professor Todd Hankinson (University of Colorado School of Medicine and Children’s Hospital Colorado, USA)
- Professor Juan Pedro Martinez-Barbera (UCL Great Ormond Street Institute of Child Health, UK)
Register Today: https://bit.ly/2M8qvF5